Fusion Antibodies PLC Exercise of Options and Total Voting Rights (2114I)

TIDMFAB

RNS Number : 2114I

Fusion Antibodies PLC

10 August 2021

Fusion Antibodies plc

("Fusion" or the "Company")

Exercise of Options and Total Voting Rights

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has made an application to the London Stock Exchange for the admission to trading on AIM ("Admission") of 23,334 new ordinary shares of 4p each in the Company ("New Ordinary Shares"). The New Ordinary Shares are being issued pursuant to the exercise of options by an employee of the Company. The options were issued pursuant to the Company's EMI Employee Share Option Scheme with an exercise price of 54.5p. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares and Admission is expected to become effective on 17 August 2021.

Total Voting Rights

On Admission, the issued share capital of the Company will comprise 25,894,946 ordinary shares of 4 pence each with one voting right per share ("Ordinary Shares"). The Company does not hold any Ordinary Shares in treasury. Therefore, from Admission, the total number of Ordinary Shares and voting rights in the Company will be 25,894,946. From Admission, the above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

 
 Fusion Antibodies plc                                                   www.fusionantibodies.com 
 Richard Jones, Chief Executive Officer                                           Via Walbrook PR 
  James Fair, Chief Financial Officer 
 
 Allenby Capital Limited                                                      Tel: +44 (0)20 3328 
                                                                                             5656 
 James Reeve (Corporate Finance) 
  Tony Quirke (Sales and Corporate Broking) 
 
 Walbrook PR                                    Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com 
 Anna Dunphy                                                                 Mob: +44 (0)7876 741 
                                                                                              001 
 Paul McManus                                                                Mob: +44 (0)7980 541 
                                                                                              893

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx (TM) platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.

The global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $63.2 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRPMMFTMTMBBRB

(END) Dow Jones Newswires

August 10, 2021 12:08 ET (16:08 GMT)

Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Mar 2024 to Apr 2024